000908 *ST景峰医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-74.8402,684.856-500.552-54.114-43.523
总资产报酬率 ROA (%)-4.90315.228-18.754-7.585-6.887
投入资产回报率 ROIC (%)-8.18023.837-30.059-11.048-9.446

边际利润分析
销售毛利率 (%)64.64062.80071.75876.28862.087
营业利润率 (%)-9.05749.004-26.322-8.127-15.401
息税前利润/营业总收入 (%)-8.71449.229-23.423-4.084-7.205
净利润/营业总收入 (%)-15.91838.326-34.626-11.331-23.506

收益指标分析
经营活动净收益/利润总额(%)75.984-31.53569.97558.938249.946
价值变动净收益/利润总额(%)-3.377159.891-14.854-16.140-177.348
营业外收支净额/利润总额(%)40.421-23.91511.15620.22013.530

偿债能力分析
流动比率 (X)0.3900.2510.2050.5270.498
速动比率 (X)0.3250.2020.1430.4160.384
资产负债率 (%)104.300101.610116.47086.16682.557
带息债务/全部投入资本 (%)64.85978.67392.29570.98770.087
股东权益/带息债务 (%)12.23916.776-11.59825.43231.484
股东权益/负债合计 (%)4.0738.564-5.70513.12119.678
利息保障倍数 (X)-1.3435.084-3.775-0.669-0.679

营运能力分析
应收账款周转天数 (天)64.94560.09167.16879.197143.424
存货周转天数 (天)134.025126.489179.444249.019226.966